{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:34:58Z","timestamp":1778394898504,"version":"3.51.4"},"reference-count":59,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Servicios Sociales e Igualdad","doi-asserted-by":"publisher","award":["Retic-ISCIII, RD16\/017\/010"],"award-info":[{"award-number":["Retic-ISCIII, RD16\/017\/010"]}],"id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Servicios Sociales e Igualdad","doi-asserted-by":"publisher","award":["Plan Nacional sobre Drogas 2018\/007"],"award-info":[{"award-number":["Plan Nacional sobre Drogas 2018\/007"]}],"id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Economia y Competitividad","award":["PID2019-104077RB-100"],"award-info":[{"award-number":["PID2019-104077RB-100"]}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["CEX2018-000792-M"],"award-info":[{"award-number":["CEX2018-000792-M"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["BES-2017-080066"],"award-info":[{"award-number":["BES-2017-080066"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>3,4-Methylenedioxypyrovalerone (MDPV) is a new psychoactive substance (NPS) and the most widespread and life-threatening synthetic cathinone of the \u201cbath salts\u201d. Preclinical research has proven the cocaine-like psychostimulant effects of MDPV and its potential for abuse. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid that has emerged as a new potential treatment for drug addiction. Here, we tested the effects of CBD (20 mg\/kg) on MDPV (2 mg\/kg)-induced conditioned place preference and MDPV (0.05 and 0.075 mg\/kg\/infusion) self-administration paradigms. In addition, we assessed the effects of the co-administration of CBD and MDPV (3 and 4 mg\/kg) on anxiety-like behaviour using the elevated plus maze (EPM). CBD mitigated the MDPV-induced conditioned place preference. On the contrary, CBD administration throughout the MDPV (0.075 mg\/kg\/infusion) self-administration increased drug-seeking and taking behaviours, but only in the high-responders group of mice. Furthermore, CBD exerted anxiolytic-like effects, exclusively in MDPV-treated mice. Taken together, our results indicate that CBD modulation of MDPV-induced motivational responses in mice varies depending on the requirements of the learning task, resulting in a complex response. Therefore, further research attempting to decipher the behavioural and molecular interactions between CBD and MDPV is needed.<\/jats:p>","DOI":"10.3390\/ijms22158304","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T08:44:11Z","timestamp":1627893851000},"page":"8304","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cannabidiol Modulates the Motivational and Anxiety-Like Effects of 3,4-Methylenedioxypyrovalerone (MDPV) in Mice"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-8469","authenticated-orcid":false,"given":"Laia","family":"Alegre-Zurano","sequence":"first","affiliation":[{"name":"Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"L\u00f3pez-Arnau","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Pharmacology Section and Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1.","family":"Luj\u00e1n","sequence":"additional","affiliation":[{"name":"Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Camarasa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Pharmacology Section and Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-7852","authenticated-orcid":false,"given":"Olga","family":"Valverde","sequence":"additional","affiliation":[{"name":"Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain"},{"name":"Neuroscience Research Programme, IMIM-Hospital del Mar Research Institute, 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"ref_1","unstructured":"United Nations Publication (2020). World Drug Report, United Nations Publication."},{"key":"ref_2","unstructured":"EMCDDA (2020). European Drug Report 2020: Trends and Developments."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1570159X13666141210225009","article-title":"Cathinone Neurotoxicity (\u201cThe \u201c3Ms\u201d)","volume":"13","author":"Karch","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/7854_2016_53","article-title":"Neuropharmacology of 3,4\u2013Methylenedioxypyrovalerone (MDPV), Its metabolites, and related analogs HHS Public Access","volume":"32","author":"Baumann","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neuropharm.2017.10.007","article-title":"MDPV and \u03b1-PVP use in humans: The twisted sisters","volume":"134","author":"Karila","year":"2018","journal-title":"Neuropharmacol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.amjmed.2012.02.019","article-title":"Psychoactive \u201cbath salts\u201d intoxication with methylenedioxypyrovalerone","volume":"125","author":"Ross","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/npp.2012.204","article-title":"Powerful cocaine\u2013like actions of 3,4\u2013methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive \u2018bath salts\u2019 products","volume":"38","author":"Baumann","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/adb.12479","article-title":"Comparing rewarding and reinforcing properties between \u201cbath salt\u201d 3,4\u2013methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats HHS Public Access","volume":"23","author":"Simmons","year":"2018","journal-title":"Addict. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00213-017-4709-3","article-title":"Role of hypocretin\/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats","volume":"234","author":"Simmons","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109876","DOI":"10.1016\/j.pnpbp.2020.109876","article-title":"Cross\u2013reinstatement between 3,4\u2013methylenedioxypyrovalerone (MDPV) and cocaine using conditioned place preference","volume":"100","author":"Puster","year":"2020","journal-title":"Prog. Neuro\u2013Psychopharmacol. Biol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/acschemneuro.7b00510","article-title":"Dopamine D1\u2013like receptor agonist and D2\u2013like receptor antagonist (\u2212)\u2013stepholidine reduces reinstatement of drug\u2013seeking behavior for 3,4\u2013methylenedioxypyrovalerone (MDPV) in rats","volume":"9","author":"Hicks","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173032","DOI":"10.1016\/j.pbb.2020.173032","article-title":"Conditioned place preference following concurrent treatment with 3, 4-methylenedioxypyrovalerone (MDPV) and methamphetamine in male and female Sprague-Dawley rats","volume":"198","author":"Risca","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neuropharm.2017.11.034","article-title":"Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)","volume":"134","author":"Sewalia","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00213-015-4057-0","article-title":"Reinforcing and neurochemical effects of the \u201cbath salts\u201d constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy\u2013N\u2013methylcathinone (methylone) in male rats","volume":"233","author":"Schindler","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuropharm.2018.05.008","article-title":"Self\u2013administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism","volume":"137","author":"Geste","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00213-014-3819-4","article-title":"Binge\u2013like acquisition of 3,4\u2212methylenedioxypyrovalerone (MDPV) self\u2013administration and wheel activity in rats","volume":"232","author":"Aarde","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuropharm.2013.04.003","article-title":"The novel recreational drug 3,4\u2013methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats","volume":"71","author":"Aarde","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00213-015-3944-8","article-title":"In vivo potency and efficacy of the novel cathinone \u03b1 \u2013 pyrrolidinopentiophenone and 3,4\u2013methylenedioxypyrovalerone: Self\u2013administration and locomotor stimulation in male rats","volume":"232","author":"Aarde","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1369-1600.2012.00474.x","article-title":"Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)","volume":"19","author":"Watterson","year":"2014","journal-title":"Addict. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.116.239376","article-title":"Individual differences in the relative reinforcing effects of 3,4\u2013methylenedioxypyrovalerone under fixed and progressive ratio schedules of reinforcement in rats","volume":"361","author":"Gannon","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/npp.2012.233","article-title":"In vivo effects of abused \u201cbath salt\u201d constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity","volume":"38","author":"Fantegrossi","year":"2013","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.drugalcdep.2017.06.031","article-title":"Effects of orally self-administered bath salt constituent 3,4\u2013methylenedioxypyrovalerone (MDPV) in mice","volume":"179","author":"Gannon","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.06.005","article-title":"Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre\u2013clinical and clinical findings","volume":"167","author":"Elsaid","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1871527313666140612114838","article-title":"Antidepressant\u2013like and anxiolytic\u2013like effects of cannabidiol: A chemical compound of Cannabis sativa","volume":"13","author":"Coutinho","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guti\u00e9rrez, M.S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., and Manzanares, J. (2020). Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules, 10.","DOI":"10.3390\/biom10111575"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The Endocannabinoid System and Cannabidiol\u2019s Promise for the Treatment of Substance Use Disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors","volume":"8","author":"Varani","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Calpe-L\u00f3pez, C., Pilar Garc\u00eda-Pardo, M., and Aguilar, M.A. (2019). Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms. Molecules, 24.","DOI":"10.3390\/molecules24142583"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"172982","DOI":"10.1016\/j.pbb.2020.172982","article-title":"Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review","volume":"196","author":"Rodrigues","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuropharm.2018.09.043","article-title":"Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus","volume":"143","author":"Valverde","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_34","first-page":"e12778","article-title":"The pharmacological reduction of hippocampal neurogenesis attenuates the protective effects of cannabidiol on cocaine voluntary intake","volume":"25","author":"Cantacorps","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alegre-Zurano, L., Luj\u00e1n, M.\u00c1., Cantacorps, L., Mart\u00edn-S\u00e1nchez, A., Garc\u00eda-Baos, A., and Valverde, O. (2020). Cannabidiol effects on cocaine\u2013seeking behaviour and incubation of craving in mice. BioRxiv.","DOI":"10.1101\/2020.12.18.423391"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","article-title":"Effect of low doses of 9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats","volume":"175","author":"Parker","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/0269881118799954","article-title":"Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats","volume":"32","author":"Hay","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"118271","DOI":"10.1016\/j.lfs.2020.118271","article-title":"Behavioural and molecular effects of cannabidiolic acid in mice","volume":"259","author":"Valverde","year":"2020","journal-title":"Life Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.npp.1300707","article-title":"Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration","volume":"30","author":"Soria","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00213-008-1184-x","article-title":"A reliable method to study cue-, priming-, and stress-induced reinstatement of cocaine self-administration in mice","volume":"199","author":"Soria","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lujan, M.A., Alegre-Zurano, L., Martin-Sanchez, A., and Valverde, O. (2020). The effects of cannabidiol on cue- and stress-induced reinstatement of cocaine seeking behavior in mice are reverted by the CB1 receptor antagonist AM4113. BioRxiv.","DOI":"10.1101\/2020.01.23.916601"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pbb.2015.07.013","article-title":"Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences","volume":"137","author":"King","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"173065","DOI":"10.1016\/j.pbb.2020.173065","article-title":"Cannabidiol (CBD) reduces cocaine-environment memory in mice","volume":"199","author":"Chesworth","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110390","DOI":"10.1016\/j.pnpbp.2021.110390","article-title":"Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice","volume":"111","author":"Ledesma","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bcp.2019.02.004","article-title":"7,8\u2013Dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: Differential role of the BDNF\u2013TrkB pathway","volume":"163","author":"Camarasa","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuropharm.2018.10.005","article-title":"Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV","volume":"144","author":"Valverde","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"209875","DOI":"10.1155\/2014\/209875","article-title":"Synthetic cathinones and their rewarding and reinforcing effects in rodents. The Rise of Synthetic Cathinone Use and Abuse","volume":"2014","author":"Watterson","year":"2014","journal-title":"Adv. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.biopsych.2007.09.003","article-title":"CB1Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and Reinforcement","volume":"63","author":"Ledent","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41386-018-0209-3","article-title":"The abuse\u2013related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter","volume":"43","author":"Gannon","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1007\/s00213-019-05339-4","article-title":"Self\u2013administration of the synthetic cathinones 3,4\u2013methylenedioxypyrovalerone (MDPV) and \u03b1\u2013pyrrolidinopentiophenone (\u03b1\u2013PVP) in rhesus monkeys","volume":"236","author":"Collins","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00213-021-05764-4","article-title":"MDPV \u201chigh\u2013responder\u201d rats also self-administer more oxycodone than their \u201clow-responder\u201d counterparts under a fixed ratio schedule of reinforcement","volume":"238","author":"Gannon","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e12783","DOI":"10.1111\/adb.12783","article-title":"Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents","volume":"25","author":"Bi","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107740","DOI":"10.1016\/j.neuropharm.2019.107740","article-title":"Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5\u2013TH1A and TRPV1 receptor mechanisms","volume":"167","author":"Galaj","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00213-018-5052-z","article-title":"Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine","volume":"236","author":"Aster","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pbb.2014.09.021","article-title":"3,4-Methylenedioxypyrovalerone (MDPV)-induced conditioned taste avoidance in the F344\/N and LEW rat strains","volume":"126","author":"King","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/dev.21171","article-title":"Age-dependent MDPV-induced taste aversions and thermoregulation in adolescent and adult rats","volume":"56","author":"Merluzzi","year":"2014","journal-title":"Dev. Psychobiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus\u2013maze","volume":"100","author":"Chiaretti","year":"1990","journal-title":"Psychopharmacology"},{"key":"ref_59","first-page":"1002","article-title":"Pharmacological characterization of cannabinoids in the elevated plus maze","volume":"253","author":"Onaivi","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/15\/8304\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:39:07Z","timestamp":1760164747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/15\/8304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":59,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22158304"],"URL":"https:\/\/doi.org\/10.3390\/ijms22158304","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202106.0642.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}